What Calmurid Treats: Main Uses and Benefits

Support for Severe Dryness and Hyperkeratotic Conditions

The therapeutic application of Calmurid (Urea and Lactic Acid cream) is commonly used across domains where additional symptomatic support is needed for the skin, focusing on managing specific symptom patterns and conditions related to dryness and texture abnormalities. This preparation is relevant in clinical settings marked by uncomfortable dryness, tightness, and the flaking of the skin in conditions like Ichthyosis or chronic Xerosis. The cream is commonly used in the management of dermatoses characterized by hyperkeratosis, a category encompassing conditions like Psoriasis, Keratosis Pilaris, and localized hard skin.

The primary therapeutic benefit is offering supportive relief that helps to ease the overall symptom burden, particularly the tightness, irritation, and itching (pruritus) associated with severe skin dryness. It is relevant for managing symptoms that interfere with daily comfort, such as roughness and scaling. The use of this combination contributes to easing the overall symptom load during symptomatic phases by assisting with the smoothing and softening of the skin. This specialized support is commonly used in situations involving recurrent or episodic manifestations of chronic skin disorders, contributing to improved comfort during symptomatic periods by easing the overall symptom load.

---

Quick Fact Block

Quick Fact: Supportive Management of Dry, Rough Skin
Symptom Category	Symptoms related to physical discomfort (dryness, scaling, itching)
Typical Use Context	Management of recurrent or episodic manifestations
Primary Benefit	Contributes to easing the overall symptom load and assists with maintaining functional stability

Regulatory References

1. Summary of Product Characteristics from the Health Products Regulatory Authority (HPRA)

Who Can and Cannot Use Calmurid?

Regulatory documents define eligibility for Calmurid (Urea 10%/Lactic Acid 5% w/w Cream) based on specific patient populations, skin integrity, and concurrent health status.

---

Contraindications and Restrictions

Category	Regulatory Status	Constraint Details
Absolute Contraindication	Must not use	Patients with known hypersensitivity (allergy) to the active ingredients (Urea or Lactic Acid) or any excipients are ineligible.
Skin Integrity	Application Prohibited	Must not be applied to inflamed skin, open wounds, the eyes, eyelids, lips, or other mucous surfaces.
Organ Function	Conditional Use	Extensive use in subjects with severe renal impairment is restricted and requires medical supervision.

---

Approved Age Groups and Life Stages

Official labeling indicates that Calmurid is suitable for use in the adult, paediatric (children), and older people populations under standard conditions.

Pregnancy and Lactation:

• Pregnancy: No specific data is available regarding use. Use in this population is conditional upon advice from a healthcare professional.
• Breastfeeding: The cream must be removed from the breast area before breastfeeding to prevent ingestion by the infant.

---

The official eligibility profile permits use across all general age groups while strictly excluding those with known hypersensitivity. All other limitations are conditional, based either on the application site (e.g., open wounds) or specific medical status (e.g., severe kidney impairment).

The official interaction profile for Calmurid (Urea and Lactic Acid cream) is primarily defined by the Topical Exposure-Altering Interaction caused by its composition, and not by systemic metabolic interactions. The regulatory documents state that the Urea component of the cream may enhance the penetration of co-administered active substances into the skin. This documented effect is considered for other topical medicines, particularly those explicitly listed in official labeling.

Documented Interacting Topical Agents

Interacting Medicinal Product	Type of Interaction Described
Topical Corticosteroids (e.g., Hydrocortisone)	Urea may enhance skin penetration.
Dithranol (Anthralin)	Urea may enhance skin penetration.
5-Fluorouracil	Urea may enhance skin penetration.

Official Regulatory Notes

The interaction profile includes a Physicochemical Stability Interaction, where the low pH of the cream is documented as a factor that might affect the stability of other drugs if applied concurrently. No mandatory timing-based rules for separating the administration of topical products are specified. Furthermore, the regulatory basis notes the absence of documented systemic interactions involving metabolic enzymes (CYP450) or drug transporters, which is consistent with its topical route. A population-specific caution related to clearance is also noted: the product should not be used extensively in subjects with severe renal impairment without medical supervision due to the potential for transcutaneous absorption of urea. No interactions with food, alcohol, or herbal products are documented in official sources.

Mechanism of Action on Stratum Corneum

Calmurid's mechanism is based on the combined local effects of urea and lactic acid on the stratum corneum, the outermost epidermal layer. The interaction involves two principal mechanistic domains: hydration modulation and keratolytic action.

Urea's Role in Natural Water-Binding Factor Modulation

Urea (10%) acts mechanistically as a humectant, actively attracting and binding to water molecules within the stratum corneum. This action modulates the activity of the skin's Natural Water-Binding Factor components, facilitating increased water binding and modulating the structure of keratin proteins. This engagement with hydration dynamics results in altered physical properties of the tissue.

Lactic Acid's Keratolytic Pathway Engagement

Lactic acid (5%) and urea contribute to a keratolytic effect by engaging pathways that facilitate the disruption of the intercellular cement binding the dead skin cells (corneocytes) together. This mechanism involves modulation of the natural process of desquamation (shedding). The targeted interference with these adhesive bonds modulates the detachment of aggregated cellular layers, impacting superficial tissue structure.

Official Administration Guidelines

Entity	Description (Regulatory Statement)
Route of administration	The preparation is for cutaneous use only, intended for application to the skin surface.
Dosing schedule	Apply an amount sufficient to cover the affected areas. The quantity is determined by the specific region being treated.
Frequency pattern	The standard application frequency is twice daily or as directed by the treating physician.
Age-group rules	The standard twice-daily application regimen is specified for use in adults, the paediatric population, and older people.

---

Preparation and Administration Specifics

The correct method of application involves a standardized sequence, starting with skin preparation. Application is advised to be performed ideally after washing the affected skin area. The procedural steps then guide the user to:

• Apply a thick layer of the cream to the targeted area.
• Allow the cream to remain on the skin for 3 to 5 minutes as a contact period.
• Subsequently, rub the cream in gently.
• Any excess cream remaining on the skin surface should be wiped off with a tissue.

Special Procedural Conditions

Application must adhere to specific limitations. Use is restricted, and the preparation should be kept away from the eyes and surrounding area, as well as other mucous surfaces. The cream must not be applied to inflamed skin or open wounds.

A temporary, label-based administration adjustment is also provided: if local smarting is encountered during initial application, the cream may be diluted 50% with aqueous cream B.P. for one week before resuming the full-strength formulation. The duration of application is determined by the clinician.

Recent Clinical Evidence Overview

The formulation of Calmurid, which includes the active ingredients urea (typically 10%) and lactic acid (typically 5%), has been the subject of research concerning its dermatological effects, particularly for conditions characterized by dry, scaly, or rough skin, such as ichthyosis and various forms of dermatitis.

Studies generally focus on the dual action of its components: urea as a humectant (water-retaining agent) and a keratolytic (skin-softening agent), and lactic acid as a mild keratolytic and an aid to urea stabilization. The clinical evidence describes the preparation as an emollient and keratolytic agent.

---

Research on Hydration and Barrier Function

Clinical trials involving urea-based creams have been performed to objectively characterize improvements in skin hydration and scaling. Research using non-invasive techniques, such as measurements of electrical capacitance and conductance, has demonstrated a relationship between increased skin hydration parameters and clinical improvement in dryness among participants. Some studies have noted a decrease in transepidermal water loss (TEWL) following treatment with urea cream, which may indicate an improved water barrier function in the skin.

---

Tolerability and Safety Findings

Safety assessments across multiple studies indicate that urea-lactic acid creams are generally well-tolerated. The most frequently reported adverse event is mild, transient stinging or irritation, which is usually related to application on sensitive, damaged, or broken skin. In research involving the use of urea creams as a supplement to other topical medications, urea has been observed to potentially enhance the penetration of those substances.

Common questions about Calmurid (FAQ)

Q: What is Calmurid and how is it used?

Calmurid is a moisturizing cream used to treat dry, scaly skin conditions. It is a combination product containing urea and lactic acid.

• Urea works as a humectant (a substance that attracts and holds water), increasing the skin's moisture content.
• Lactic acid acts as a mild keratolytic, which helps to soften and shed the top layer of dry, rough skin.

It is typically applied to the affected areas of skin, usually once or twice daily, or as directed by a healthcare provider.

---

Q: What are the main side effects of Calmurid?

The most common side effects of Calmurid are usually mild and temporary and may include:

• Mild stinging or burning sensation when first applied, especially on broken or very sensitive skin.
• Redness or irritation.

These effects often lessen with continued use as the skin condition improves. If you experience severe irritation, a rash, or signs of an allergic reaction (like swelling or difficulty breathing), you should stop using the cream immediately and consult a healthcare professional.

---

Q: Can Calmurid be used on the face?

Calmurid is primarily intended for use on the body to treat scaly and dry skin conditions. While it may be applied to the face under a healthcare provider's direction, caution is generally advised because the face is often more sensitive than other areas of the body. The urea and lactic acid content can cause increased irritation or stinging on the delicate facial skin.

• Avoid contact with the eyes, nose, mouth, and other mucous membranes.
• If used on the face, a small test area should be tried first.

Always follow the specific instructions given by your healthcare professional or the product label regarding application areas.

---

Q: How long does it take for Calmurid to start working?

The time it takes for Calmurid to show noticeable results can vary depending on the severity of the skin condition, how regularly the cream is applied, and individual response. Some people may notice an improvement in skin moisture and softness within a few days of starting treatment. However, it may take several weeks of continuous, consistent use to see the full therapeutic effect, particularly for more severe scaly conditions. It is important to continue using Calmurid as prescribed or directed for the best results.

How to Store and Dispose of Calmurid

Calmurid (Urea and Lactic Acid Cream) must be stored strictly according to official regulatory conditions to maintain its stability. The cream must not be stored above 25 C and it is mandated not to be refrigerated or frozen. Equivalent US formulations specify storage at Controlled Room Temperature (20 C to 25 C) and require protection from excessive heat and freezing. The container must be kept tightly closed.

For safety, the medicine must be stored out of the sight and reach of children.

Disposal instructions advise discarding unused or expired product according to local regulations, with specific warnings not to dispose of the cream via wastewater or household waste to protect the environment. The official shelf-life for the unopened product is two years.